Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.
Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference2%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe website has removed several links to external resources related to rare diseases and clinical trials, as well as specific sections on participant groups and treatment interventions.SummaryDifference4%
- Check35 days agoChange DetectedNew resources have been added, including links to rare disease information, clinical trial documents, and drug information for Paclitaxel and Pembrolizumab.SummaryDifference0.4%
- Check43 days agoChange DetectedThe website has been updated to include new features for downloading study data in various formats and has upgraded to revision v2.12.2, while removing the option to show less information and the previous revision v2.12.1.SummaryDifference4%
- Check50 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.